Ameloblastoma – Causes, Symptoms and Treatment
Ameloblastoma is a rare, benign but locally aggressive tumor of the jawbone that originates from tooth-forming (odontogenic) epithelial tissue and most commonly affects the lower jaw.
Wissenswertes über "Ameloblastoma"
Ameloblastoma is a rare, benign but locally aggressive tumor of the jawbone that originates from tooth-forming (odontogenic) epithelial tissue and most commonly affects the lower jaw.
What Is an Ameloblastoma?
An ameloblastoma is a rare tumor arising in the jawbone from the enamel organ epithelium – the tissue responsible for forming dental enamel during tooth development. Although it is classified as a benign (non-cancerous) tumor in most cases, it grows in a locally aggressive manner and can cause significant destruction of the jawbone. Malignant transformation, while uncommon, can occur. Ameloblastoma accounts for approximately 1% of all oral tumors and about 10% of all odontogenic (tooth-related) tumors.
Causes and Origin
The exact causes of ameloblastoma are not fully understood. It is believed to arise from remnants of the enamel-forming epithelium that persist in the jaw after tooth development. Factors under discussion include:
- Residual enamel organ tissue (dental follicle remnants) within the jawbone
- Epithelial linings of jaw cysts (e.g., dentigerous cysts)
- Genetic alterations, particularly BRAF gene mutations (V600E mutation), identified in a large proportion of cases
- Basal cells of the oral mucosa
Ameloblastoma most commonly presents between the ages of 30 and 60 and affects males and females equally. Approximately 80% of cases involve the mandible (lower jaw), particularly the molar region.
Types of Ameloblastoma
The World Health Organization (WHO) recognizes several distinct subtypes:
- Conventional (solid/multicystic) ameloblastoma: The most common form, locally aggressive with a high recurrence rate
- Unicystic ameloblastoma: Predominantly affects younger patients, less aggressive, typically presents as a single cyst-like lesion
- Extraosseous (peripheral) ameloblastoma: Very rare, arises in the soft tissue of the gingiva rather than the bone
- Metastasizing ameloblastoma: Rarest subtype, histologically benign but capable of forming distant metastases
- Ameloblastic carcinoma: The malignant variant, exhibiting cytological features of malignancy
Symptoms
Ameloblastoma typically grows slowly and painlessly over many years, which means it is often diagnosed late. Common signs and symptoms include:
- Slowly progressive, painless swelling of the jaw or face
- Expansion and deformity of the jawbone
- Loosening or displacement of teeth
- Difficulty swallowing or opening the mouth in larger tumors
- Occasional numbness in the jaw or lip region
- Incidental finding on dental X-rays
Diagnosis
Diagnosis of ameloblastoma is based on a combination of imaging studies and histological examination:
Imaging
- Panoramic radiograph (OPG): Typically reveals a soap-bubble or multilocular radiolucency within the jaw
- Computed tomography (CT): Provides detailed assessment of tumor extent and bone destruction
- Magnetic resonance imaging (MRI): Useful for evaluating soft tissue involvement
Tissue Analysis
- Biopsy with histopathological examination: Confirms the diagnosis by microscopic analysis of tumor tissue
- Molecular pathology: Detection of BRAF mutations to guide treatment planning
Treatment
Treatment depends on the tumor subtype, location, and extent of involvement. Given the high recurrence potential of ameloblastoma, radical surgical resection remains the gold standard of care.
Surgical Treatment
- Radical resection: Removal of the tumor with adequate margins of healthy bone; the preferred approach for conventional ameloblastoma
- Conservative enucleation/curettage: May be considered for unicystic forms, but carries a higher risk of recurrence
- Reconstruction: Following major jaw resection, bone reconstruction is commonly performed using autologous bone grafts (e.g., free fibula flap)
Medical and Adjuvant Therapy
- In inoperable or recurrent cases with confirmed BRAF V600E mutation, targeted therapy with BRAF inhibitors (e.g., vemurafenib, dabrafenib) may be considered
- Radiation therapy and chemotherapy play a limited role in benign ameloblastoma but may be relevant in ameloblastic carcinoma
Follow-Up and Prognosis
The prognosis following complete surgical removal is generally favorable; however, long-term follow-up is essential due to the high risk of recurrence. Recurrences can appear years or even decades after initial treatment. Regular clinical examinations and imaging follow-up (X-ray, CT) are strongly recommended.
References
- Wright JM, Vered M. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors. Head and Neck Pathology, 2017; 11(1): 68–77.
- Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO. Ameloblastoma: current etiopathological concepts and management. Oral Diseases, 2018; 24(3): 307–316.
- Brown NA, Betz BL. Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. Biomarkers in Cancer, 2015; 7(Suppl 2): 19–24.
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryLipid Metabolism Optimization Markers
Lactate Tolerance Markers
Vital Nutrient Biokinetics
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Cologne list
Calorie content
Related search terms: Ameloblastoma + Ameloblastomata + Ameloblastomas